Page 2456 - Williams Hematology ( PDFDrive )

2427
2426 Index Index 2427

fusion proteins, 169–170, 1016–1017 for inherited platelet disorders, 2062 Error catastrophe theory, 130
histone modification, 167–168, 167f mechanism of action, 2317 Ertapenem, 384, 387t
trained immunity, 168 pharmacology, 2317–2318 Erwinia chrysanthemi, 332
Epinephrine for von Willebrand disease, 2176 Erwinia chrysanthemi-derived asparaginase,
for allergic transfusion reactions, 2375 εγδβ-thalassemia, 735, 745, 751 1515
for evaluation of neutrophil reserves, 943 εωδβ-thalassemia, 726 Erythema multiforme (EM), 2106, 2106f
for mastocytosis, 976 Epstein-Barr virus (EBV) infections Erythremic myelosis, 1390
neutrophilia and, 1001 aplastic anemia and, 518 Erythroblastic islands (EBIs), 64, 462–463,
neutrophil motility and, 1026 Burkitt lymphoma and, 1265, 1573, 1672, 462f
in platelet activation, 1876 1674 Erythroblasts
Epinephrine receptor defects, 2057 differential diagnosis, 1269, 1513 basophilic, 463f, 464, 464f
Epipodophyllotoxins, 328–329. See also epidemiology, 1261–1262 differentiation, 64
Etoposide; Teniposide future therapeutic approaches, 1266 enucleation, 481–482
Epirubicin, 327–328 Hodgkin lymphoma and, 1604, 1605 iron in, 623–624
adverse effects, 328, 1519t infectious mononucleosis. See Epstein-Barr marrow, 32t, 34
for enteropathy-associated T-cell virus (EBV) mononucleosis maturation, 465–467, 466f, 467f
lymphoma, 1700 lymphomas and, 1573, 1576, 1599 normal, 465
for Hodgkin lymphoma, 1611 neoplastic potential, 1265–1266, 1266t numbers, 481, 482t
Epistaxis posttransplant lymphoproliferative orthochromic, 463f, 465, 465f
in Bernard-Soulier syndrome, 2049 disorders and, 1636 pathologic, 465, 466f
etiology, 1987 primary CNS lymphoma and, 1246 polychromatophilic, 463f, 464–465, 465f
in factor V deficiency, 2139 T-cell–receptor signaling defects and, 1220 precursors, 463–465, 463f, 464f
in hemophilia, 2120, 2122t, 2123 T-cell therapy, 411–412 primitive, 100, 100f
history of, 5 in X-linked lymphoproliferative disease, proerythroblasts, 463–464, 463f, 464f
therapy, 2062 1228–1229, 1266 progenitors, 64, 463
in von Willebrand disease, 2172 Epstein-Barr virus (EBV) mononucleosis release, 72
Epithelial progenitor cells (EPCs), 450, 451 clinical manifestations, 1262–1263, 1263t reticulocytes. See Reticulocytes
Epitopes, 2336 complications, 1263t, 1265 Erythrocytapheresis
EPO. See Erythropoietin (EPO) course and prognosis, 1265 adverse effects, 433
EPO, 485 epidemiology, 1263 for hereditary hemochromatosis, 432
EPOCH regimen laboratory features, 1264–1265, 1264f, indications for, 429t, 430t
for diffuse large B-cell lymphoma, 1629t, 1267t for polycythemia vera, 432
1630 secondary leukocytosis in, 1202 principles, 432
for HIV-associated lymphoma, 1243–1245, treatment, 1269 Erythrocyte antibodies, 2343–2350,
1247 virology and pathogenesis, 1262 2344–2346t
for primary mediastinal large B-cell Eptifibatide, 405 in autoimmune hemolytic anemia. See
lymphoma, 1634 for acute coronary syndrome, 2077 Autoimmune hemolytic anemia
EPO-EPOR signaling, 484–485, 486f clinical uses, 404t, 405 fetal production, 2347
Epoetin, 554. See also Erythropoiesis- dosage, 404t in hemolytic disease of the fetus and
stimulating agents (ESAs) mechanism of action, 405, 2045, 2077 newborn, 2348. See also Hemolytic
EPOR. See Erythropoietin receptor (EPOR) for sickle cell disease, 777t disease of the fetus and newborn
EPOR, 232t, 485, 873, 873t thrombocytopenia and, 2015, 2077 immunoglobulin A, 2347
EPP. See Erythropoietic protoporphyria EPX (eosinophil-derived neurotoxin), 931, immunoglobulin G, 2343
(EPP) 953 immunoglobulin M, 2343, 2347
ε-aminocaproic acid (EACA) EPZ-5676, 1403 immunology, 2343
adverse effects, 2318 Equilateral branching, 2153 naturally occurring, 2347
for bleeding in thrombocytopenia, 2003, Er antigens, 2333t in response to immunization, 2347–2348
2007 Erdheim-Chester disease, 1101, 1102t, serologic detection, 2350
for bleeding not response to platelet 1110–1111 in transfusion reactions, 2348. See also
transfusion, 2385 ERGIC (endoplasmic reticulum-Golgi Transfusion reactions
in cardiopulmonary bypass, 2086 intermediate compartment Erythrocyte antigens, 2327–2350. See also
for combined deficiency of factors V and protein)-53, 1171 Blood group systems
VIII, 2140 ERK (extracellular signal-regulated kinase), antibodies to. See Erythrocyte antibodies
for disseminated intravascular coagulation, 298, 1103 biochemistry, 2337, 2338f
2214 ERK1, 1529 carbohydrate, 2337
for hemophilia A, 2123 Erlenmeyer flask deformity, 1124, 1125f collections, 2333t

Kaushansky_index_p2393-2506.indd 2427 9/21/15 3:21 PM